Evidence map›Paper›PMID 31386094›Full record

ArticleNeuro-oncology practice2015

Early cognitive function tests predict early progression in glioblastoma.

Soon-Tae Lee, Chul-Kee Park, Jin Wook Kim, Min-Jung Park, Hyon Lee, Jung-Ah Lim, Seung Hong Choi, Tae Min Kim, Se-Hoon Lee, Sung-Hye Park and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Preoperative nonmedical predictors of functional impairment after brain tumor surgery.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Soon-Tae LeeDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Chul-Kee ParkDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Jin Wook KimDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Min-Jung ParkDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Hyon LeeDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Jung-Ah LimDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Seung Hong ChoiDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Tae Min KimDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Se-Hoon LeeDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Sung-Hye ParkDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Il Han KimDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).
Kyoung-Min LeeDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (S.-T.L., H.L., J.-A.L., K.-M.L.); Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea (C.-K.P., J.W.K., M.-J.P.); Department of Radiology, Seoul National University Hospital, Seoul, Korea (S.H.C.); Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea (T.M.K., S.-H.L.); Department of Pathology, Seoul National University Hospital, Seoul, Korea (S.-H.P.); Department of Radiation Oncology,Seoul National University Hospital, Seoul, Korea (I.H.K.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly progression of glioblastoma prevents patients from completing the standard chemoradiation protocol. Given that cognitive function is associated with prognosis in glioblastoma, we investigated the usefulness of preoperative cognitive function tests for predicting the early progression of glioblastoma.

methodsConsecutive patients who underwent glioma surgery were preoperatively evaluated with cognitive function tests including the Mini Mental State Examination, digit span tests, the Controlled Oral Word Association Test, the Trail Making Tests (TMT, parts A, B, and C), and the Stroop test. Glioblastomas were treated with a standard protocol using radiation and temozolomide, and 6-month progression-free survival (PFS-6) was analyzed retrospectively.

resultsAmong 126 patients who underwent glioma surgery, 55 patients were diagnosed with glioblastoma, and 50 patients were eligible for the PFS-6 analysis. Thirty-four patients (68%) achieved PFS-6. No significant differences were observed in demographics or tumor characteristics between patients without progression (PFS-6) or patients with progression (no-PFS-6). In the cognitive function tests, the PFS-6 patients exhibited better performance in TMT-A and TMT-B. In a multivariate logistic regression, TMT-B was the only independent predictor for PFS-6, whereas age, years of education, gross total or near total resection, concomitant chemoradiation, and TMT-A were not predictors. Patients with good TMT-B performance exhibited better early prognosis in the Kaplan-Meier survival analysis and had better recursive partitioning analysis classes.

conclusionsOur results indicated that preoperative TMTs can be useful for rapid evaluation of early prognosis in patients with glioblastoma.

Indexed as

6-month progression-free survivalcognitive function testglioblastomatrail making test

Identifiers

PMID31386094
PMCPMC6668270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.